Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- pSivida Corp. announced its second Phase 3 trial of Durasert three-year treatment for posterior segment uveitis achieved the trial's primary endpoint. The primary endpoint was reportedly prevention of recurrence of posterior uveitis at six months with patients continuing to be followed for 36 months. Durasert three-year insert reportedly demonstrated a significant reduction in the recurrence of posterior segment uveitis through six months — 21.8 percent of Durasert-treated patients had a recurrence, compared to 53.8 percent of patients in the sham group.
- Applied Genetic Technologies Corporation (AGTC) reported topline safety data for the dose escalation phase of the company’s Phase 1/2 X-linked retinoschisis (XLRS) clinical trial, a program partnered with Biogen. The findings are reportedly consistent with previous results demonstrating that the company's investigational gene therapy for XLRS was generally well tolerated and demonstrated a good safety profile across treatment groups.
- Technology-based pharmaceutical company Verseon will present preclinical results on its plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME) at the 2017 BIO International Conference next week in San Diego. The presentation will reportedly include pharmacokinetic data indicating that Verseon’s drug candidates can be administered as eye drops.
- Scientists at the CSIR-Centre for Cellular and Molecular Biology in India have reportedly developed a new treatment for fungal keratitis, according to an article on BioSpectrumIndia.com. The new treatment reportedly uses a drug encapsulated within protein-based nanoparticles to help keep it from being washed away by tears. The capsule is broken down by enzymes secreted by the fungus, releasing the drug.
- And LumiThera® Inc. — a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease — was recently awarded the "Most Innovative and Promising MedTech & E-Health Company" award during Biovision 2017 in Lyon, France.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.